GENFIT to receive US$20M milestone after Ipsen’s Iqirvo® exceeds the US$200M threshold in its first full year of net sales Ipsen reported US$88M of Iqirvo® net sales in PBC for 4Q25, bringing 2025 sales to US$208M, triggering the first commercial milestone payment to GENFIT ahead of schedule1Ipsen confirmed its commitment to launch a Phase 3 in PSC, creating a new avenue for potential future upside for GENFITGENFIT’s CCA Phase 1b study progressing as planned: New dose-escalation cohort fully enrolled with no dose-limiting toxicities reported at the 21-day timepoint Phase 1b data readout ...
GENFIT va recevoir un paiement d’étape de 20 M$ suite au dépassement du seuil des 200 M$ de ventes nettes d’Iqirvo® par Ipsen dès sa première année complète de commercialisation Ventes nettes d’Iqirvo® dans la PBC par Ipsen atteignant 88 M$ au 4T25, portant le total annuel pour 2025 à 208 M$, déclenchant le premier paiement d’étape1 commercial pour GENFIT plus tôt que prévu Confirmation par Ipsen du lancement d’une Phase 3 dans la PSC, ouvrant une nouvelle opportunité de création de valeur potentielle pour GENFITL’étude de Phase 1b de GENFIT dans le CCA progresse comme prévu : Nouvelle coho...
Adyen: New Platforms partnership in APAC / Dutch Pension Reform (Wtp): 1/3 transitioned (c.25 funds), 2027 challenging / IBA: Sale of a P1 system to MacKay Memorial Hospital in New Taipei City, Taiwan / KPN: 4Q25 preview / Offshore Wind: North Sea offshore wind pact to develop 300GW by 2050 / Vår Energi: RRR 2P 185% offsets slight pressure on expected production volumes 4Q
Yesterday at a North Sea summit the Hamburg Declaration was signed by energy ministers from Belgium, Denmark, France, Germany, Ireland, Luxembourg, the Netherlands, Norway and the United Kingdom with Iceland joining as an observer. The governments agreed to work towards up to 100 GW of cross-border offshore wind capacity in the North Seas by 2050, while also advancing offshore renewable hydrogen as part of a more integrated regional energy system European governments committed to derisking offsh...
Today we resume our coverage on SIF with a Neutral recommendation, and a TP of € 7.1. If SIF in the coming 12 months is able to deliver on its 2026 guidance, and refill its 2027 & 2028 order backlog with new large contracts, the stock has large upside potential. If they do not deliver, the stock has further downside potential.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.